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1Introduction
This monograph on lung 
cancer has been prepared 
to provide information on 
patterns of practice to those
directly involved in the 
provision of care to lung 
cancer patients. As well, it
should be helpful to those 
who are responsible for 
managing aspects of the 
cancer system that impact 
on the care that lung cancer
patients receive across the
province of Ontario. The 
practice patterns are shown
against the backdrop of the 
evidence-based guidelines 
developed by the Lung Disease
Site Group of Cancer Care 
Ontario’s Program in Evidence-
based Care. In addition to 
information on patterns of 
practice, this monograph 
provides information on the
timeliness of access to care, 
as well as a brief overview of
the incidence and mortality 
of lung cancer, and the trends 
in the main risk factor for 
developing lung cancer, namely
smoking. In brief, it provides 
a snapshot of the quality of
care for lung cancer patients 
in the province of Ontario. 
It is hoped that this monograph
will assist those responsible
for care delivery to achieve 
the best possible results for
patients with a diagnosis of
lung cancer.
Incidence of Lung Cancer
Lung cancer is the most 
common cause of death due 
to cancer in Canada. In 2003, 
it is estimated that there will
be 21,100 new cases and 18,800
deaths from lung cancer. In
Ontario, it is estimated that
there will be 7,500 new cases
and 6,300 deaths from lung
cancer. Figure 1 shows the
incidence of lung cancer by
gender over the past 10 years.
Although the overall incidence
is higher in men, there has been
a steady decrease in the inci-
dence of lung cancer in men in
the past 10 years. In contrast,
the incidence rate among women
has been steadily increasing. 
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Risk Factors
Lung cancer is the most 
preventable of all human cancers.
Cigarette smoking is the main
cause of lung cancer and it
should be no surprise to anyone
that changes in the incidence 
of lung cancer run parallel to
changes in smoking habits.
Individuals who have been
smoking for the past several
decades are the ones now being
diagnosed with lung cancer.
Twenty years ago there were
record numbers of women,
including teenagers, who were
smoking regularly. The number
of men smoking at that time, 
in all age groups, had begun to
decline. The trends in smoking
rates among men and women
over the past decade are shown
in Figure 2 and Figure 3. As
fewer people are smoking today,
it is anticipated that lung cancer
rates will be lower in the future.
Nonetheless, aggressive 
anti-smoking measures must
continue, as the proportion of
the population smoking is still
approximately 19%. Factors
helping to reduce smoking
include strict anti-smoking
bylaws, cigarette taxation,
smoking cessation programs,
and school and public education
programs. 
Mortality from Lung Cancer
Figure 4 shows the mortality
rate (death rate per 100,000 
population) from lung cancer
for both men and women over
the past decade. The graph for
mortality is similar to that for
incidence, in that men show 
a decline in mortality, whereas
women show an increasing 
mortality rate.
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Figure 1 Lung Cancer Incidence Rates in Ontario, 1991–2001
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Figure 2 Smoking Rates for Lung Cancer by Age — Male
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Lung Cancer Survival
The overall survival rate for lung
cancer is poor, in part because
it is most often diagnosed at an
advanced and incurable stage.
Only about 25% of all lung 
cancers are, potentially, surgically
resectable. Approximately 35%
of patients have extension of
cancer to involve lymph nodes
centrally in the chest (mediastinal
lymph nodes) and about 40%
have cancer spread outside of
the chest. Figure 5 shows that
the two-year survival does not
vary much between regions,
although the survival in the south
is significantly worse than the
rest of Ontario, while survival 
in the east is significantly better.
Survival for all of Ontario is
indicated by the blue horizontal
line. 
Assessing Consistency of
Practice Against Evidence-
based Recommendations
The recent development of a
software called DS-Web has
made it possible to rapidly 
interrogate a number of admin-
istrative databases, including
the Ontario Cancer Registry, the
Oncology Patient Information
System (OPIS) and the New
Drug Funding Program (NDFP)
database. Amongst other things,
DS-Web can rapidly determine
the volume of clinical activity 
in any cancer centre across 
the province and analyze radio-
therapy and systemic therapy
clinical practice patterns. Where
stage information is available, it
is now possible to describe the
stage-specific treatment practices.
In the future it should be possible
to assess stage-specific survival.
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Figure 3 Smoking Rates for Lung Cancer by Age — Female
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Source: Cancer Care Ontario (Ontario Cancer Registry, 2003)
Figure 4 Lung Cancer Mortality Rates in Ontario, 1991–2001
0
10
20
30
40
50
60
70
80
90
100
1991 1993 1995 1997 1999 2001
Year of diagnosis or death
Male mortality Female mortality
A
g
e-
st
an
d
ar
d
iz
ed
 r
at
e 
p
er
 1
0
0
,0
0
0
(3
-y
ea
r 
m
o
vi
n
g
 a
ve
ra
g
es
)
Source: Cancer Care Ontario (Ontario Cancer Registry, 2003)
In the paragraphs that follow,
the recommendations for treat-
ment by type and stage of lung
cancer are described and then
the actual clinical practices 
are displayed for each of the
regional cancer centres.
For more information on 
DS-Web, send inquiries to 
DS-Web@cancercare.on.ca.
Practice Guidelines and the
Treatment of Lung Cancer
The Provincial Lung Disease Site
Group (DSG) is one of 14 DSGs
that develop evidence-based
practice guidelines and evidence
summaries as part of Cancer
Care Ontario’s Program in
Evidence-Based Care. The Lung
DSG has 31 members from
across the province representing
the disciplines of thoracic 
surgery, radiation therapy and
systemic therapy. As well, the
DSG has a medical sociologist, 
two research coordinators and 
two patient representatives. 
The DSG has completed and
published 14 guidelines on 
various aspects of treatment 
for different forms and stages 
of lung cancer. These guidelines
can be found on Cancer 
Care Ontario’s Web site, 
www.cancercare.on.ca/
access_PEBC.htm. The details
found in these guidelines are
briefly summarized below.
Management of Early Stage Non
Small Cell Lung Cancer (NSCLC)
For those patients presenting
with early stage lung cancer
(Stages I and II), the usual 
treatment is surgical removal
(resection), assuming the patient
can tolerate an appropriate
operation. For those individuals
who have very poor pulmonary
function or other major 
co-morbidities that prevent 
pulmonary resection, local
radiotherapy may be used to
control the tumour. For those
patients undergoing surgical
resection, roughly half survive
five years. The survival rate
depends on factors such as the
size of the tumour, the extent 
of lymph node involvement by
cancer found at surgery and the
tumour histology. In the most
favourable situation — a tumour
less than three centimeters in 
maximum diameter, without
spread to intrapulmonary lymph
nodes and with squamous 
histology — the survival is
approximately 70%–80% at five
years. Some patients are sent 
for consideration of adjuvant
chemotherapy or radiotherapy
after complete resection of 
a lung cancer. The Lung DSG,
which has reviewed the evidence
for adjuvant therapies, has 
concluded that there are no data
to support the use of radiotherapy
in patients who have had a com-
plete resection of their tumour.
The data on the use of adjuvant
chemotherapy is conflicting, but
recent studies suggest that there
may be a small survival benefit.
Management of Locally
Advanced NSCLC
Patients are most commonly
referred to a cancer treatment
facility with a diagnosis of cancer
when the disease is considered
to be inoperable. Lung cancer is
inoperable but locally advanced
when it has extended beyond
what a surgeon can resect for
cure, but is still confined to 
the chest (Stage III). For those
patients who have mediastinal
lymph nodes involved by tumour
(lymph nodes located around
the central structures in the
chest), but who have a good
performance status and have
not lost more than 5% of their
usual body weight in the 
preceding three months, the 
evidence supports the use of 
a combination of chemotherapy
and radical radiotherapy. 
4
Figure 5 Lung Cancer Estimated* Two-Year Relative Survival †
by Region, Age-Adjusted, 2000–2001 
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* Estimated with Brenner’s period method, which estimates survival of all cases under 
follow-up during 2000-2001, adjusted for age 
† Bars = survival estimates, I = 95% confidence intervals
5Observations on the
Treatment of Locally
Advanced NSCLC at
Regional Cancer Centres 
The data displayed below 
was extracted from several 
of Cancer Care Ontario’s 
administrative databases — the
Oncology Patient Information
System and the New Drug
Funding Program’s databases —
using DS-Web. In order to 
evaluate practice relative to 
evidence-based recommenda-
tions, it was necessary to select
only those cases for whom stage
information was recorded in the
chart electronically. The capture
of stage information has improved
at all cancer centres but is still
incomplete. This accounts for
the modest number of cases seen
in some analyses. 
Radiation Therapy
Figure 6 provides information on
the radiotherapeutic management
of Stage III non-small cell lung
cancer (NSCLC) patients treated
with curative intent at each
regional cancer centre. The 
recommended amount of 
radiotherapy (60 Gray) requires
six weeks of therapy and 30 
fractions (treatments). A boost
of radiation may be given so
that more than 30 fractions
could be given. While most 
centres employ this approach,
some use fewer fractions. This
may reflect the fact that there
are other radical dose schedules 
in use including 50Gy in 
20 fractions and even 48Gy in 
12 fractions. The lower fraction
number may also be due to
errors of coding the intent of
treatment, failure to complete
the prescribed course of 
radiation therapy, a belief that
lesser amounts of radiotherapy
may be sufficient, or a case mix
with a greater proportion of
poor performance status patients
who would not be candidates
for radical radiotherapy. 
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Figure 6 Percentage of Stage III NSCLC Treated with Curative Intent Showing Number of
Radiation Treatments, Jan – Dec 2002
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Legend for Figures 6–10
Ham = Hamilton, KNG = Kingston, LND = London, NEO = Northeastern Ontario, NOW = Northwestern Ontario,
OTT = Ottawa, TSB = Toronto Sunnybrook, WND = Windsor, RCC = Regional Cancer Centre
Chemotherapy
The chemotherapy used in the
combined modality approach 
to locally advanced lung cancer
can be one of several different
regimens, but should include
the drug cisplatin. It has been
demonstrated that a survival
advantage can be achieved
when both chemotherapy and
radiotherapy are used together.
The Provincial Lung DSG does
not recommend a specific
chemotherapy regimen, but there
are a number of chemotherapy
regimens that are acceptable.
The initial trials, demonstrating
increased survival with combined
modality therapy, used the 
two-drug combination vinblastine
and cisplatin (CISPVINB). A trial
performed by the Southwest
Oncology Group (SWOG), in
concert with the National Cancer
Institute of Canada (NCIC),
used etoposide-cisplatin 
(CISPET) for the treatment of
Pancoast tumours (tumours 
at the apex of the lung), and
demonstrated enhanced local
control and improved survival.
Vinorelbine-cisplatin (VINOCISP)
has been shown to be one of the
most effective regimens available
for the treatment of advanced
disease, and it has been tested
in an adjuvant trial through 
the NCIC. Based on these trial
results, oncologists are using
one of these regimens in 
combination with radiotherapy.
As can be seen in Figure 7a, 
two centres use predominantly
vinblastine-cisplatin (CISPVINB),
two use predominantly etoposide-
cisplatin or etoposide-carboplatin
(CISPETOP/CISPET-RT/
ETOPCARBO), and two use
predominantly vinorelbine-
cisplatin (VINOCISP). Figure 7b
shows that 83% of the
chemotherapy usage for Stage III
disease is consistent with one 
of these approaches and this is
consistent with the practice
guideline recommendations. 
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Figure 7a Percentage of Stage IIIb NSCLC Patients Treated by Specific Chemotherapy
Regimen, Jan – Dec 2002
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7Stage III can be divided into IIIa
and IIIb disease. One group of
Stage IIIa patients (those with 
a relatively low volume of
lymph node disease in the 
mediastinum on the same side
as the tumour) can be candidates
for chemotherapy before surgery
(neoadjuvant chemotherapy).
The most commonly used 
regimens for neoadjuvant
chemotherapy include 
etoposide-cisplatin, vinorelbine-
cisplatin, and vinblastine-
cisplatin, which are all acceptable
approaches. Vinorelbine-
carboplatin is being used in a
small percentage of these cases.
Although it is well tolerated, 
it is a more expensive regimen
and has not been well studied 
in Stage III disease.
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Figure 7b Percentage of Stage IIIb NSCLC Patients Treated by Specific Chemotherapy
Regimen Consistent with Provincial Guidelines, Jan – Dec 2002
0%
20%
40%
60%
80%
100%
HAM
21
KNG
13
LND
23
NEO
6
NWO
7
OTT
41
TSB
11
WND
10
ALL RCC
132
Regional Cancer Centre
N
u
m
b
er
 o
f T
re
at
ed
 C
as
es
# of Cases:
VINOREL
VINO/CARBO
OTHER
GEMCIT
CONSISTENT
WITH
GUIDELINES
Consistent with
Guidelines:
- VINOCISP
- CISPVINB
- CISPETOP
Source: Cancer Care Ontario (Oncology Patient Information System, 2003)
Figure 8a Percentage of First-Line Systemic Treated Cases by Specific Chemotherapy Regimen
for Non-Small Cell Lung Cancer — Stage IIIa, Jan – Dec 2002
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Figure 8b Percentage of Stage IIIa NSCLC Patients Treated with Chemotherapy Consistent
with Provincial Guidelines, Jan – Dec 2002
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Figure 9a Percentage of First-Line Systemic Treated Cases by Specific Chemotherapy Regimen
for Non-Small Cell Lung Cancer — Stage 4, Jan – Dec 2002
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Management of Metastatic
Non-Small Cell Lung Cancer
The management of Stage IV
NSCLC is dependent on the 
performance status of the patient,
as well as the willingness of the
patient to accept treatment with
its trade-offs of drug-induced
toxicities and modest survival
and quality of life gains. 
Four different combination
chemotherapy regimens have
been shown to have similar
response rates and survival but
they differ in their toxicities and
convenience of administration.
Some require multiple visits to 
a treatment centre each month,
whereas others are administered
on a once every three week
schedule. Depending on the
patient’s clinical situation, 
particularly other medical 
conditions, one regimen may be
superior to another. For example,
taxol-carboplatin and vinorelbine-
cisplatin are associated with
nerve injury (neuropathy).
Neither regimen would be the
preferred option in the setting
of a pre-existing neuropathy.
Unless there are clinical 
reasons to use a different 
drug regimen, the Lung DSG
recommends vinorelbine-cisplatin
as the first line treatment 
standard, in view of its proven
benefit in terms of response
rate, survival, and low cost. 
For patients who have difficulty
with intra-venous access, pre-
existing peripheral neuropathy
or severe constipation, the 
gemcitabine-cisplatin regimen is
recommended by the Lung DSG
as a first-line choice. The Policy
Advisory Committee for the
New Drug Funding Program 
has recently approved both 
taxotere-cisplatin and taxol-
cisplatin/carboplatin as potential
first-line options. Previously,
taxotere was only available 
as a second-line therapy after 
first-line therapy with a regimen
such as vinorelbine-cisplatin.
Specific clinical circumstances
should dictate the choice of 
regimen where vinorelbine-
cisplatin is not possible and a
treatment decision algorithm
has been developed to guide
physician decision-making.
Figure 9a shows the percentage
use of different chemotherapy
regimens for Stage IV NSCLC
patients by treatment centre. 
It can be seen that vinorelbine-
cisplatin, which is the 
recommended standard, is 
most commonly used in two
centres (Ottawa, Northwestern
Ontario), vinorelbine alone is
used predominantly in one 
CLINICAL FOCUS ON LUNG CANCER
centre (Hamilton), and several
centres use a variety of regimens,
perhaps reflective of the case
mix seen. Vinorelbine alone 
is considered appropriate in 
elderly patients and those who
would not tolerate cisplatin-
related toxicities. It is not 
recommended by the Lung DSG
as a standard therapy in those
who can tolerate cisplatin. Even
though vinorelbine-carboplatin
may have less side effects than
the standard vinorelbine-cisplatin,
it is not considered an acceptable
regimen because of the lack of
data on its efficacy relative to
other regimens that have been
carefully tested in clinical trials.
Figure 9b shows that 72% of 
the regimens being administered
are acceptable according to
provincial guidelines. Vinorelbine
(VINOREL) alone is included as
acceptable in this analysis, but
not vinorelbine-carboplatin
(VINO/CARBO).
Management of Small Cell
Lung Cancer
Small cell lung cancer makes 
up about 15% of all lung cancer
cases. At least two-thirds of
patients present with widespread
disease with metastases to organs
outside of the chest. This is
referred to as extensive disease.
Limited disease refers to disease
confined to the thorax. In the
latter situation, patients are
treated with a combination of
chemotherapy and radiotherapy.
The Lung DSG’s practice guideline
for limited stage small cell lung
cancer recommends etoposide-
cisplatin (CISPETOP/CISPET-RT)
as the standard chemotherapy
regimen. Etoposide-carboplatin
(ETOPCARBO) is also considered
acceptable. Figure 10 shows that
for patients with both limited
and extensive lung cancer, these
are the dominant regimens
used. An NCIC clinical trial has
shown that the use of CAV 
(a combination of three drugs —
cyclophosphamide, Adriamycin
and vincristine) alternating with
etoposide-cisplatin is superior to
using CAV alone. Some clinicians
still use this alternating regimen,
which yields similar results to
etoposide-cisplatin alone and 
is consistent with provincial
practice guidelines. The data
from the regional cancer centres
indicate that virtually all cases
are treated with regimens that
are consistent with the practice
guideline recommendations
made by the Lung DSG. 
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Figure 9b Percentage of Stage IV NSCLC Patients Treated with Chemotherapy Consistent with
Provincial Guidelines, Jan – Dec 2002
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Figure 10 Percentage of Small Cell Lung Cancer Cases Treated with Chemotherapy Regimen —
Not TMN Staged, Jan – Dec 2002
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Role of Palliative Care
Palliative care plays a very
important role in the management
of lung cancer patients because,
as noted in the section on lung
cancer mortality, the five-year
survival of lung cancer patients
is less than 15%. Most patients
would benefit from a palliative
care team to assist in symptom
management, psychosocial 
support, and attention to spiritual
needs. Unfortunately, there is
little information about the pro-
portion of patients who actually
have access to such important 
supportive care and palliative
care assistance. In some cancer
treatment facilities, palliative
care clinics have been 
established to support 
the needs of cancer patients
generally, and particularly
those with symptoms that 
are proving difficult to manage
with conventional medical 
interventions.
Future initiatives should 
optimize the integration of 
supportive care and palliative
care services into the manage-
ment of the lung cancer patient.
And there is a need for more
data on the proportion of
patients who are provided such
care and the degree to which
their symptoms are palliated.
Access to Cancer
Treatment — Wait Times
It is not known at what point
waiting for cancer treatment can
lead to physical harm. Intuitively,
it makes sense to begin treatment
as promptly as possible after the
diagnosis of cancer. On the other
hand, cancer takes many years
to reach a size that is clinically
detectable, so several weeks or
months of waiting, depending
on the tumour site may actually
have little or no impact on 
the ultimate disease outcome,
although waiting does affect the
patient’s quality of life. There
are data to show that anxiety
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Figure 11 Lung Cancer Radiation Therapy Wait Times, 2000 Q1 to 2003 Q1
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Figure 12 Lung Cancer Systemic Therapy Wait Times, 2000 Q1 to 2003 Q1
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Centre Weeks
Hamilton Regional Cancer Centre 3.9
Kingston Regional Cancer Centre 2.7
London Regional Cancer Centre 1.9
Northeastern Ontario Regional Cancer Centre 3.9
Northwestern Ontario Regional Cancer Centre 2.9
Ottawa Regional Cancer Centre 3.0
Princess Margaret Hospital 1.0
Toronto Sunnybrook Regional Cancer Centre 2.0
Windsor Regional Cancer Centre 4.7
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levels are high for people awaiting
a diagnosis, and again from
diagnosis to the actual start 
of treatment. In this context, 
the Canadian Association of
Radiation Oncologists recom-
mends that the time interval
from referral to the start of
treatment should be no longer
than four weeks. There are,
however, no standards for 
wait times for surgery or the
administration of chemotherapy.
There is not much data available
concerning wait times for lung
cancer surgery. From a study of
surgical wait times at hospitals
associated with cancer centres
in Ontario and published in the
Canadian Medical Association
Journal in August of 2001, the
average wait time from referral
to surgery was 36 days. Recent
wait time data from the Princess
Margaret Hospital, University
Health Network, suggests an
even more serious waiting time
problem. Time from referral 
to operation had grown from 
36 days for lung cancer patients
in January of 2001 to 70 days in
March of 2003. The rate limiting
steps appear to be access to
operating rooms and the avail-
ability of specialized personnel,
including anaesthetists.
Chemotherapy treatment does
not have the same resource 
constraints as radiation therapy
or surgery. Therefore, waiting
times for chemotherapy are gen-
erally shorter. Where wait times
exceed four weeks from referral
to treatment, the underlying
cause is usually either a shortage
of medical oncology consultants
or poor access to imaging studies
(CT or MRI scan), which are
necessary to assess the disease
extent prior to the start of treat-
ment. Figures 11 and 12 show
the average wait times (50th
percentile and 90th percentile)
for radiation and systemic therapy
from referral to treatment.
Cancer Care Ontario now 
posts wait time information 
on its Web site, which displays
the median (average) wait
times from referral to treatment
for the preceding three months
www.cancercare.on.ca/
access_waitTimes.htm. 
These wait times are updated
monthly based on data from
the regional cancer centres and
Princess Margaret Hospital. The
table below shows the median
wait time from referral to start
of treatment for lung cancer,
by centre, for the three-month
period of May to July 2003.
The benchmark time interval
from referral to treatment 
for lung cancer is four weeks 
and, as can be seen, almost 
all radiotherapy treatment 
centres achieve this standard.
However, it should be noted
that the wait times apply to
both radical and palliative
cases. Palliative cases may 
be seen in rapid access 
palliative clinics where the
consultation, planning and
treatment are all given on 
the same day. This practice 
will tend to average down 
the wait times and patients
requiring radical therapy 
may be expected to have 
wait times that are longer 
than those posted.
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Conclusions
Lung cancer is one of the most
common malignancies in Ontario
and the leading cause of cancer
deaths. 
Waiting times to access a 
consultation with a medical or
radiation oncologist for lung
cancer are not excessive and
times from consult to treatment
are generally modest. The average
(median) wait time from referral
to treatment in most regional
cancer centres and the Princess
Margaret Hospital is less than
the four week target set by
Cancer Care Ontario.
Unfortunately, there is less data
available on waiting times for
surgery or on other important
quality issues such as surgical
resection rates and peri-operative
mortality. The Surgical Oncology
Program is currently addressing
these data deficiencies and
developing quality indicators.
However, Ontario has a long 
history of excellence in thoracic
surgery and it is highly probable
that measures of quality will
rate highly in thoracic surgical
oncology, with the exception of
timeliness of access.
Lung cancer commonly presents
in an advanced stage of disease,
which precludes surgical 
resection for cure. For locally
advanced disease, a combination
of chemotherapy and radio-
therapy is recommended for
patients who are well enough 
to receive this combination 
of therapies and Cancer Care
Ontario’s guideline recommen-
dation appears to have been
adopted in regional cancer 
centres. The available data 
does not allow us to determine
if all patients who could 
potentially benefit from this
therapy actually receive it. 
For metastatic non-small cell
lung cancer, a variety of 
cisplatin-based chemotherapy
regimens can be used to palliate
symptoms and prolong survival
for those patients who are of
good performance status and
who have not lost significant
amounts of weight. Practices in
regional cancer centres appear
to be consistent with evidence-
based practice guidelines.
However, there is no data to
inform us as to whether all 
candidates who could benefit
from this therapy receive it.
For small-cell lung cancer,
chemotherapy is the backbone
of treatment, and most 
patients receive the two-drug
chemotherapy regimen etoposide-
cisplatin. Practice within regional
cancer centres is uniformly 
consistent with evidence-based
recommendations.
Overall, the data from the
Decision Support Unit using 
DS-Web show a high degree 
of consistency of practice with
guideline recommendations 
generated by the Lung DSG of
Cancer Care Ontario’s Practice
Guidelines Initiative.
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Glossary of Terms
Adjuvant chemotherapy
The use of anti-cancer drugs after
surgery to decrease the chance
of the cancer coming back.
Adjuvant therapy
A treatment method used in
addition to the primary therapy;
used to increase the effectiveness
of treatment.
Age-standardized rate
The number of new cases of 
cancer or cancer deaths per
100,000 that a population would
have if it had a standard age
structure. Standardization is 
necessary when comparing several
populations that differ with
respect to age because age has
such a powerful influence on 
mortality and morbidity indicators.
Age-specific rate
The number of new cases of 
cancer or cancer deaths during
the year, expressed as a rate 
per 100,000 persons in a given
age group.
Chemotherapy
A drug or combination of drugs
used to kill cancer cells and fight
cancer.
Combination chemotherapy
Treatment using two or more
anti-cancer medications.
Combined modality therapy
Two or more types of treatment
are given either at the same time
or in sequence; may include
combinations of radiation,
chemotherapy, surgery, or others.
Five-year relative survival
A measure of the reduction in
life expectancy due to a diagnosis
of cancer. Relative survival is
estimated from life tables as the
ratio of the observed survival 
of cancer cases five years after
diagnosis to the expected survival
of individuals of the same age 
in the general population.
Fraction
Dose of radiation for a single
treatment.
Incidence
A rate showing how many new
cases of a disease occurred in a
population during a specified
interval of time (usually expressed
as number of new cases per unit
time per fixed number of people;
e.g., number of new cases of
cancer per 100,000 persons in
one year). 
Locally advanced cancer
Cancer that has spread only to
nearby tissues or lymph nodes.
Lymph nodes
Small bean-shaped organ that
acts as a filter to collect bacteria
and other foreign substances
from the lymphatic system to be
processed by the immune system.
Metastasis
The spread of cancer cells from
the original site to other parts of
the body.
Modality
A type or kind of treatment (sur-
gery, chemotherapy, radiotherapy).
Multimodality therapy
Therapy that combines more than
one method of treatment such as
chemotherapy and radiation.
Neoadjuvant therapy
Therapy given before the primary
treatment to treat a cancer to
improve the effectiveness of the
primary treatment; neoadjuvant
therapy can be chemotherapy or
radiation therapy.
Non-small cell lung cancer
The most common histological
type of lung cancer; includes
adenocarcinoma, squamous cell
carcinomas, large cell anaplastic
and bronchial alveolar carcinomas.
Ontario Cancer Registry
The population-based database
that includes information on all
diagnoses of cancer reported in
Ontario since 1964. It includes
limited data about diagnosis
(date, type of cancer), death
(date, cause), treatment, and 
the individual (date of birth, sex,
census division of residence at
diagnosis/death) for all cancer
patients. It does not include data
on risk factors, stage, grade, or
non-melanoma skin cancers.
Prevalence
The total number of active cancer
cases in the population at the
current moment in time.
Radiation treatment
X-ray treatment that damages or
kills cancer cells.
Regimen
The plan that outlines the
dosage, schedule and duration 
of treatment.
Regional involvement
The spread of cancer from 
its original site to nearby 
surrounding areas.
Risk factors
Anything that may increase a
person’s chance of developing
cancer. It may be an activity,
such as smoking, diet, family
history, environmental agents 
or many other things. 
Side effect
An effect on the body caused
by cancer treatment other than
the effect on the cancer; also
called adverse reaction.
Small cell lung cancer
A histological type of lung cancer
characterized by rapid growth
clinically and characteristic
small cells as seen under the
microscope.
Staging
A method to describe the size 
of a tumour and the extent of 
its spread.
Standard treatment
Treatment that has been proven
effective and is commonly used.
Surgical resection
Removing tissue from the body
through a surgical procedure.
Systemic disease
Disease that affects the whole
body rather than only an organ.
Systemic treatment
Treatment that reaches cells 
all over the body by travelling
through the bloodstream.
Three-year moving average
Rate calculated using the sum of
the new cases of cancer or cancer
deaths for a three-year period
and the population estimates for
those same years. Three-year
moving average rates are shown
on all graphs describing trends
in order to smooth out annual
fluctuation.
Tumour histology
The type of cancer as classified
by its appearance under the
microscope.
Unresectable
Cannot be surgically removed.
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